To validate whether AXT could potentially suppress invadopodia formation and the consequent suppression of metastasis, metastatic colon cancer cells (CT26 and HCT116) were treated with AXT for 24 h, followed by metastatic analysis through wound and transwell matrigel invasion assays. The gene discussed is CNTN2; the disease is malignant colon neoplasm.